Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in African-American/Black Subjects with HFrEF
NCT03456856Phase 4Completed
- Sponsor
- Amgen
- Start
- Sep 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ivabradine in heart failure with reduced ejection fraction (HFrEF), sponsored by Amgen. Started Sep 2017; status: completed.
02
Drugs
ivabradine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03456856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456856.